Effectiveness of CelluTome Epidermal Harvesting System in Autologous Skin Grafting of Chronic Wound Patients
Status: | Withdrawn |
---|---|
Conditions: | Hospital |
Therapuetic Areas: | Other |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 4/17/2018 |
Start Date: | December 16, 2014 |
End Date: | December 2018 |
This is multi-center prospective, longitudinal case series with comparison to historical
controls.
controls.
The primary objective to this study is to determine the effectiveness of CelluTome™ epidermal
harvesting system as an outpatient skin grafting system for selected patients versus
inpatient skin graft harvest. This is multi-center prospective, longitudinal case series with
comparison to historical controls. In this study, all subjects will receive the same
treatment protocol regardless of institution. This will include routine wound photography.
Ongoing healing process will be recorded and reviewed. The secondary objectives of this study
are to establish an ideal donor site size, recipient site size and ideal patient population
(especially high operative risk patients) that would benefit from the use of CelluTome™
Epidermal Harvesting System.
harvesting system as an outpatient skin grafting system for selected patients versus
inpatient skin graft harvest. This is multi-center prospective, longitudinal case series with
comparison to historical controls. In this study, all subjects will receive the same
treatment protocol regardless of institution. This will include routine wound photography.
Ongoing healing process will be recorded and reviewed. The secondary objectives of this study
are to establish an ideal donor site size, recipient site size and ideal patient population
(especially high operative risk patients) that would benefit from the use of CelluTome™
Epidermal Harvesting System.
Inclusion Criteria:
- Signed Informed Consent
- Patients requiring split-thickness skin grafting with non-infected wounds
- Age of participants: 18 years and above at the time of informed consent
- Gender: Male or Female
- Subjects who will be locally available for the next 6 months.
Exclusion Criteria:
- Infected chronic wound
- Patients who are unable to adhere to scheduled study visits
- Patients who have severe arterial insufficiency requiring vascular intervention to
restore adequate blood flow
- Patients who have an active drug/alcohol dependence or abuse history
- Use of Investigational Agents/Devices on study or within 30 days prior to informed
consent or within 30 days prior to use of device.
We found this trial at
1
site
Baltimore, Maryland 21215
Principal Investigator: Noman A Siddiqui, DPM, MHA
Phone: 410-601-9467
Click here to add this to my saved trials
